Health

KFSHRC Conducts 48% of Clinical Trials in Saudi Arabia During the First Half of 2025

RIYADH, Saudi Arabia, Sept. 10, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital & Research Centre (KFSHRC) led Saudi healthcare…

3 months ago

Saudi Food and Drug Authority, AAMI Partner on Medtech Best Practices

Arlington, Virginia, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The Association for the Advancement of Medical Instrumentation (AAMI) has signed a memorandum…

3 months ago

Booking Health Expands Access to Dendritic Cell Therapy After Study Confirms Survival Benefit in Glioblastoma Patients

September 09, 2025 13:19 ET  | Source: Booking Health Langenfeld, Germany, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Booking Health, a…

3 months ago

Del Bigtree and ICAN Announce Senate Hearing on Science and Corruption, Featuring Groundbreaking Study and Announce Documentary, “An Inconvenient Study”

WASHINGTON, DC, Sept. 09, 2025 (GLOBE NEWSWIRE) -- The Informed Consent Action Network (ICAN), led by Emmy Award-winning producer and…

3 months ago

IPSEN – Buy-back programme – Art 5 of MAR – Week 36 – 2025

Aggregated presentation by day and by marketStatement of transactions in own shares from 1st September to 5th September 2025       Name of…

3 months ago

Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030

September 08, 2025 17:57 ET  | Source: Harrow, Inc. NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider…

3 months ago

Onco360 Has Been Selected as a National Specialty Pharmacy Partner for Wayrilz (rilzabrutinib)

LOUISVILLE, Ky., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a…

3 months ago

NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness

TORONTO and HAIFA, Israel, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone”…

3 months ago

InnoCare Announces Approval of HIBRUKA (Orelabrutinib) for the Treatment of Marginal Zone Lymphoma in Singapore

BEIJING, Sept. 07, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on cancer…

3 months ago

Dianthus Therapeutics to Host Conference Call and Webcast to Discuss Results from Phase 2 MaGic Trial of Claseprubart (DNTH103) in Generalized Myasthenia Gravis

September 07, 2025 18:25 ET  | Source: Dianthus Therapeutics, Inc. NEW YORK and WALTHAM, Mass., Sept. 07, 2025 (GLOBE NEWSWIRE)…

3 months ago